Piperidines
Medchemexpress LLC Ropivacaine | 84057-95-4 | 100.0% | 5 MG
Ropivacaine is a potent sodium channel blocker that blocks impulse conduction by reversibly inhibiting sodium ion influx in nerve fibers. It also acts as an inhibitor of K2P (two-pore domain potassium channel) TREK-1. It is utilized in the research of neuropathic pain management.
- Blocks impulse conduction by reversibly inhibiting sodium ion influx in nerve fibers.
- Acts as an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane.
- Utilized in the research of neuropathic pain management.
Medchemexpress LLC Ropivacaine hydrochloride monohydrate | 132112-35-7 | 99.9% | 1 ML
Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker that inhibits impulse conduction by reversibly blocking sodium ion influx in nerve fibers. It also acts as an inhibitor of K2P (two-pore domain potassium channel) TREK-1. This product is extensively used for regional anesthesia and the management of neuropathic pain in vivo.
- Potent sodium channel blocker
- Inhibits impulse conduction by blocking sodium ion influx
- Inhibitor of K2P (two-pore domain potassium channel) TREK-1
- Purity of 99.93%
- Appearance: white to off-white solid
- Recommended storage for solid: 4°C, sealed, away from moisture
- Recommended storage in solvent: -80°C for 6 months; -20°C for 1 month
Medchemexpress LLC Ropivacaine mesylate | 854056-07-8 | 99.5% | 5 MG
Ropivacaine mesylate is a long-acting amide local anaesthetic agent primarily used for spinal blocks and effective in blocking neuropathic pain. It functions by reversibly inhibiting sodium ion influx in nerve fibers, thereby blocking impulse conduction. This compound also acts as an inhibitor of the K2P (two-pore domain potassium channel) TREK-1, with an IC50 of 402.7 μM in COS-7 cell membranes.
- Functions as a long-acting amide local anaesthetic agent
- Effective for spinal blocks
- Blocks neuropathic pain
- Reversibly inhibits sodium ion influx in nerve fibers
- Inhibits K2P TREK-1 potassium channels (IC50: 402.7 μM)
- Prevents pressure-induced lung edema and hyperpermeability
- Inhibits pressure-induced nitric oxide production
Medchemexpress LLC HY-B0563B 10mg Medchemexpress, Ropivacaine hydrochloride CAS:98717-15-8 Purity:>98%
Medchemexpress, HY-B0563B 10mg Ropivacaine hydrochloride CAS:98717-15-8 Ropivacaine hydrochloride is an inhibitor of K 2P (two-pore domain potassium channel) TREK-1 with an IC 50 of 402.7 μM. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Medchemexpress LLC Ropivacaine (hydrochloride) | 98717-15-8 | 99.5% | 1 ML
Ropivacaine hydrochloride is a potent sodium channel blocker that reversibly inhibits sodium ion influx in nerve fibers to block impulse conduction. It also acts as an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. It is widely used for neuropathic pain management in vivo.
- Potent sodium channel blocker
- Reversibly inhibits sodium ion influx
- Inhibits K2P TREK-1 with an IC50 of 402.7 μM
- Used for neuropathic pain management in vivo
- Effectively blocks neuropathic pain via epidural administration
- Prevents pressure-induced lung edema and associated hyperpermeability
Apexbio Technology LLC Ropivacaine hydrochloride monohydrate 132112-35-7 50mg
Ropivacaine hydrochloride monohydrate (CAS 132112-35-7) is a long-acting amide local anesthetic widely studied for its pharmacological and electrophysiological properties It inhibits ATP-sensitive potassium (KATP) channels particularly SUR2A/Kir6 2 as demonstrated in COS-7 cell models where inhibition is concentration-dependent and reversible Reported IC50 values for SUR2A/Kir6 2 SUR2B/Kir6 1 SUR2B/Kir6 2 and Kir6 2 C36 channels are 249 11 2235 115 2442 132 and 2375 179 M respectively Additionally ropivacaine hydrochloride monohydrate suppresses sarcolemmal KATP channels in cardiovascular tissues via stereoselective and tissue-specific mechanisms supporting its utility in studies of ion channel pharmacology and cardiovascular safety profiles
Apexbio Technology LLC Ropivacaine hydrochloride monohydrate 132112-35-7 10mM (in 1mL DMSO)
Ropivacaine hydrochloride monohydrate (CAS 132112-35-7) is a long-acting amide local anesthetic widely studied for its pharmacological and electrophysiological properties It inhibits ATP-sensitive potassium (KATP) channels particularly SUR2A/Kir6 2 as demonstrated in COS-7 cell models where inhibition is concentration-dependent and reversible Reported IC50 values for SUR2A/Kir6 2 SUR2B/Kir6 1 SUR2B/Kir6 2 and Kir6 2 C36 channels are 249 11 2235 115 2442 132 and 2375 179 M respectively Additionally ropivacaine hydrochloride monohydrate suppresses sarcolemmal KATP channels in cardiovascular tissues via stereoselective and tissue-specific mechanisms supporting its utility in studies of ion channel pharmacology and cardiovascular safety profiles
Apexbio Technology LLC Vanoxerine dihydrochloride 67469-78-7 10mg
Vanoxerine dihydrochloride is a small-molecule inhibitor targeting the dopamine transporter (DAT1) human ether- -go-go-related gene (hERG Kv11 1) potassium channel cardiac sodium channel (hNaV1 5) and L-type calcium channels (ICa L) It modulates neurotransmitter uptake and cardiac ion channel conductance thereby regulating synaptic dopamine levels and cardiac electrophysiology Vanoxerine dihydrochloride exerts its biological activity primarily through inhibition of dopamine reuptake and blockade of multiple cardiac ion channels It demonstrates antagonist activity at DAT1 (Ki 16 9 nM) potent inhibition of hERG channels (IC50 0 84 nM) and inhibitory effects on hNaV1 5 (IC50 830 nM) and ICa L (IC50 320 nM) Based on these pharmacological properties vanoxerine dihydrochloride holds research potential in cardiac arrhythmia studies
Apexbio Technology LLC Vanoxerine dihydrochloride 67469-78-7 50mg
Vanoxerine dihydrochloride is a small-molecule inhibitor targeting the dopamine transporter (DAT1) human ether- -go-go-related gene (hERG Kv11 1) potassium channel cardiac sodium channel (hNaV1 5) and L-type calcium channels (ICa L) It modulates neurotransmitter uptake and cardiac ion channel conductance thereby regulating synaptic dopamine levels and cardiac electrophysiology Vanoxerine dihydrochloride exerts its biological activity primarily through inhibition of dopamine reuptake and blockade of multiple cardiac ion channels It demonstrates antagonist activity at DAT1 (Ki 16 9 nM) potent inhibition of hERG channels (IC50 0 84 nM) and inhibitory effects on hNaV1 5 (IC50 830 nM) and ICa L (IC50 320 nM) Based on these pharmacological properties vanoxerine dihydrochloride holds research potential in cardiac arrhythmia studies
Apexbio Technology LLC Vanoxerine dihydrochloride 67469-78-7 25mg
Vanoxerine dihydrochloride is a small-molecule inhibitor targeting the dopamine transporter (DAT1) human ether- -go-go-related gene (hERG Kv11 1) potassium channel cardiac sodium channel (hNaV1 5) and L-type calcium channels (ICa L) It modulates neurotransmitter uptake and cardiac ion channel conductance thereby regulating synaptic dopamine levels and cardiac electrophysiology Vanoxerine dihydrochloride exerts its biological activity primarily through inhibition of dopamine reuptake and blockade of multiple cardiac ion channels It demonstrates antagonist activity at DAT1 (Ki 16 9 nM) potent inhibition of hERG channels (IC50 0 84 nM) and inhibitory effects on hNaV1 5 (IC50 830 nM) and ICa L (IC50 320 nM) Based on these pharmacological properties vanoxerine dihydrochloride holds research potential in cardiac arrhythmia studies
Medchemexpress LLC Ropivacaine | 84057-95-4 | MFCD00078774 | 100.0% | 50 MG
Overview of Ropivacaine
Ropivacaine is a potent sodium channel blocker. It works by blocking impulse conduction through reversible inhibition of sodium ion influx in nerve fibers. Additionally, Ropivacaine acts as an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. It is utilized in the research of neuropathic pain management.
Features and Benefits
- Potent sodium channel blocker.
- Blocks impulse conduction by inhibiting sodium ion influx.
- Inhibits K2P TREK-1 (IC50 of 402.7 μM).
- Used for neuropathic pain management research.
- Epidural administration blocks neuropathic pain and delays its development.
- Inhibits pressure-induced increases in filtration coefficient.
- Prevents pressure-induced lung edema and hyperpermeability.
- Inhibits pressure-induced NO production.